New Haven-based online pharmacy Valisure’s CEO David Light spoke at the June 18 session of the WHIPgroup Tech Entrepreneur Meetup at our Stamford offices.
David and Valisure are in the news this week. They are the source for the troubling news that popular and effective acid-blocking drug Zantac and its generic form Radnitidine contain the known carcinogen NDMA.
In his talk at WHIPgroup, David led a fascinating discussion on the reasons impurities can get into the global drug supply and the tests, procedures and processes that Valisure uses to ensure their customers receive medications that are efficacious, at the right dosage, and free of harmful impurities.
If you would like to learn more about how Valisure found the NDMA in Zantac and other forms of Radnitidine, please click here.
If you would like to meet other leaders on the leading edge of technology, business and science, please join the WHIPgroup Meetup by clicking here. Our next session will be on October 15 and will explore the significant aquaculture business opportunity around Kelp farming in Long Island Sound.
The U.S. District Court for the Southern District of New York recently issued a final judgment for WHIPgroup client Koslow Technologies Corporation (Koslow) in the amount of $18M, plus full costs of $1M. The [Read More…]
The SDNY recently granted a Motion to Dismiss in favor of WHIPgroup clinet, Koslow Technologies Corporation, securing a $18M Arbitration Award. Back in March, WHIPgroup client, Koslow Technologies Corporation (Koslow), was awarded a $18M Partial [Read More…]
Infogation Corporation filed a patent infringement lawsuit in EDTX against WHIPgroup client, TomTom International B.V. TomTom International B.V., a Netherlands corporation, was never served papers related to the lawsuit. However, service was attempted on TomTom [Read More…]